Form 4: Adaptive Biotechnologies CSO Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Adaptive Biotechnologies' Chief Scientific Officer, Harlan S. Robins, sold a total of 37,212 shares of common stock in early December 2025 under a pre-arranged 10b5-1 trading plan.
Summary
- Harlan S. Robins, Chief Scientific Officer of Adaptive Biotechnologies Corp (ADPT), reported sales of common stock.
- On December 3, 2025, 27,212 shares were sold at a weighted average price of $18.61 per share, with prices ranging from $18.50 to $18.71.
- On December 4, 2025, an additional 10,000 shares were sold at a weighted average price of $16.61 per share, with prices ranging from $16.45 to $16.95.
- These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robins on August 11, 2025.
- Following these transactions, Mr. Robins beneficially owns 1,232,312 shares of common stock directly.
Sentiment
Score: 5
Explanation: The filing reports pre-scheduled insider stock sales under a 10b5-1 plan, which are generally considered neutral as they are not typically driven by immediate sentiment or new material information.
Future Outlook
This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.
Industry Context
This filing is a routine insider transaction report and does not provide information directly related to broader industry trends or competitive landscape. Insider sales under a 10b5-1 plan are common across industries for executives to manage personal finances.
Stakeholder Impact
- Shareholders may note the reduction in insider holdings, though sales under a 10b5-1 plan are pre-scheduled and typically do not signal a change in management's outlook.
Key Dates
| Date | Description |
|---|---|
| 2025-08-11 | Date Rule 10b5-1 Trading plan was adopted by Harlan S. Robins. |
| 2025-12-03 | Transaction date for the sale of 27,212 shares of common stock. |
| 2025-12-04 | Transaction date for the sale of 10,000 shares of common stock. |
| 2025-12-05 | Date the Form 4 was signed by Harlan S. Robins' attorney-in-fact. |
Recommendation
holdThe filing is a routine Form 4 reporting pre-scheduled insider sales under a 10b5-1 plan. These transactions do not typically reflect a change in management's immediate outlook on the company's prospects and therefore do not warrant a change in investment recommendation based solely on this report.
Keywords
Adaptive Biotechnologies, ADPT, Insider Trading, Form 4, Stock Sale, Harlan S. Robins, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.